Deborah D. Ascheim, M.D., joined StrideBio as Chief Medical Officer in April 2021, and in this role leads all clinical initiatives including the strategy, design and execution of clinical trials for the company’s therapeutic programs. Dr. Ascheim has spent the past 30 years as a physician, clinical investigator and director of national and international clinical trials focused on the clinical development of novel, disruptive therapeutic innovations including gene therapies that target rare and common, complex diseases. Prior roles have included, President of d2a Ltd., a strategic clinical and product development consulting firm, Chief Medical Officer of Capricor Therapeutics, Inc., and more than two decades as a heart failure cardiologist, Professor of Health Policy and Medicine (Cardiology) and Director of the International Center for Health Outcomes and Innovation Research’s Clinical Trial Unit at the Icahn School of Medicine at Mount Sinai in New York, as well as 14 years on faculty in the Department of Medicine and Division of Cardiology at the College of Physicians & Surgeons at Columbia University. Dr. Ascheim received her M.D. from New York University School of Medicine and a B.A. from Wellesley College.
Deborah Ascheim, M.D.
CHIEF MEDICAL OFFICER